Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAYER J HASBANI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology

NPI
1780632968
CMS profile
307932
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$107,504.48

494 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Avanir Pharmaceuticals, Inc. $29,050.22 47
Lilly USA, LLC $24,555.57 36
ABBVIE INC. $15,496.67 51
Kyowa Kirin, Inc. $13,144.61 16
Teva Pharmaceuticals USA, Inc. $8,075.08 39
GENZYME CORPORATION $4,141.89 17
ACADIA Pharmaceuticals Inc $3,979.79 12
Biogen, Inc. $2,756.05 19
EMD Serono, Inc. $456.17 22
Genentech USA, Inc. $448.38 12
Amneal Pharmaceuticals LLC $445.04 22
EISAI INC. $392.41 19
SK Life Science, Inc. $390.82 21
Janssen Pharmaceuticals, Inc $384.73 14
Novartis Pharmaceuticals Corporation $336.38 15
Lundbeck LLC $331.33 10
Amgen Inc. $287.52 18
Neurelis, Inc. $271.19 7
Celgene Corporation $223.20 16
Biohaven Pharmaceutical Holding Company Ltd. $216.15 9
E.R. Squibb & Sons, L.L.C. $213.62 2
Horizon Therapeutics plc $208.33 5
Alnylam Pharmaceuticals Inc. $195.19 6
Neurocrine BioSciences, Inc. $190.12 5
Abbott Laboratories $138.27 3
ARGENX US, INC. $125.01 1
UCB, Inc. $120.49 5
Collegium Pharmaceutical, Inc. $86.71 4
IMPEL PHARMACEUTICALS INC. $82.99 1
MDD US Operations, LLC $68.56 3
Mallinckrodt Hospital Products Inc. $64.96 3
PFIZER INC. $64.01 4
Avion Pharmaceuticals $62.07 4
Sunovion Pharmaceuticals Inc. $57.41 4
Banner Life Sciences, LLC $50.49 3
Grifols USA, LLC $47.40 2
JAZZ PHARMACEUTICALS INC. $41.10 2
Alexion Pharmaceuticals, Inc. $40.22 2
Scilex Pharmaceuticals Inc. $39.84 2
Currax Pharmaceuticals LLC $35.09 2
Supernus Pharmaceuticals, Inc. $24.86 1
Acorda Therapeutics, Inc $24.64 1
Organon LLC $23.32 1
Almatica Pharma LLC $22.68 1
GE HealthCare $21.15 1
CSL Behring $20.33 1
Takeda Pharmaceuticals U.S.A., Inc. $18.17 1
Allergan, Inc. $17.41 1
UPSHER-SMITH LABORATORIES LLC $16.84 1

Page 3 of 10; records 101–150 of 494 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAYER J HASBANI

NPI 1780632968 · CMS profile ID 307932

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Clinical Neurophysiology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 10; records 101–150 of 494 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780632968?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 10; records 101–150 of 494 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780632968?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 10; records 101–150 of 494 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780632968?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 10; records 101–150 of 494 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780632968?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

494 matching records · $107,504.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 494 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 494.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $74.4310/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893729855 CMS
Biogen, Inc. $2.3110/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923444865 CMS
EISAI INC. $21.1710/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910873879 CMS
Novartis Pharmaceuticals Corporation $22.3010/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893729867 CMS
Celgene Corporation $13.9010/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932544333 CMS
ABBVIE INC. $3.9210/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892761659 CMS
Teva Pharmaceuticals USA, Inc. $17.8310/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954455379 CMS
Kyowa Kirin, Inc. $4,230.0010/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905055977 CMS
Avanir Pharmaceuticals, Inc. $13.4209/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935989967 CMS
GENZYME CORPORATION $3,306.0009/29/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938933657 CMS
GENZYME CORPORATION $413.2509/29/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938933801 CMS
GENZYME CORPORATION $124.8009/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938933803 CMS
Amgen Inc. $7.1209/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939237611 CMS
Genentech USA, Inc. $129.8309/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950656577 CMS
MDD US Operations, LLC $18.8809/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965498949 CMS
Teva Pharmaceuticals USA, Inc. $16.4609/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954455211 CMS
Teva Pharmaceuticals USA, Inc. $10.8709/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954454809 CMS
Lilly USA, LLC $2,300.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918183551 CMS
Lilly USA, LLC $875.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918195827 CMS
Lilly USA, LLC $1,450.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918197077 CMS
Lilly USA, LLC $2,300.0009/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918243045 CMS
Kyowa Kirin, Inc. $882.7709/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905055979 CMS
Celgene Corporation $8.2209/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932544319 CMS
EMD Serono, Inc. $20.9309/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941559995 CMS
Mallinckrodt Hospital Products Inc. $21.0109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937501251 CMS
ABBVIE INC. $10.8509/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892761655 CMS
E.R. Squibb & Sons, L.L.C. $88.6209/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932544545 CMS
Teva Pharmaceuticals USA, Inc. $21.3909/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954455035 CMS
Avanir Pharmaceuticals, Inc. $21.9609/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935983291 CMS
EISAI INC. $8.6709/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910873877 CMS
Novartis Pharmaceuticals Corporation $16.3609/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893729853 CMS
Avanir Pharmaceuticals, Inc. $14.7409/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935982999 CMS
Biogen, Inc. $19.4509/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923389341 CMS
Lilly USA, LLC $104.6209/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918264915 CMS
PFIZER INC. $12.1109/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949341121 CMS
Biogen, Inc. $78.5808/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923428085 CMS
Collegium Pharmaceutical, Inc. $22.5208/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914536865 CMS
Lilly USA, LLC $6.5208/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918218211 CMS
Amgen Inc. $19.4808/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939237609 CMS
Amneal Pharmaceuticals LLC $14.5308/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956581175 CMS
EMD Serono, Inc. $3.3408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941556485 CMS
Horizon Therapeutics plc $27.8508/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937631499 CMS
ABBVIE INC. $2,400.0008/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892761651 CMS
Genentech USA, Inc. $21.6708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950697755 CMS
Neurocrine Biosciences, Inc. $18.4008/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963279585 CMS
ABBVIE INC. $5.2308/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892761649 CMS
Avanir Pharmaceuticals, Inc. $22.4008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935980137 CMS
Biohaven Pharmaceutical Holding Company Ltd. $3.9008/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923612355 CMS
GENZYME CORPORATION $125.0108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938933623 CMS
Alexion Pharmaceuticals, Inc. $18.4508/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915009677 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,009.76 479
PY2020 $49,267.75 387
PY2021 $83,560.62 503
PY2022 $107,504.48 494
PY2023 $80,886.83 501
PY2024 $85,002.03 514
PY2025 $105,167.91 433

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $490,883.03 48
PY2024 Principal investigator $88,369.86 24
PY2023 Principal investigator $86,758.00 28
PY2022 Principal investigator $35,146.00 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $175.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293365
Principal investigator 1 Ipsen Innovation $4,900.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293367
Principal investigator 1 Ipsen Innovation $4,970.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293369
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293371
Principal investigator 1 Ipsen Innovation $90.00 11/13/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287342
Principal investigator 1 Ipsen Pharma SAS $4,000.00 10/31/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307149
Principal investigator 1 Ipsen Innovation $90.00 10/29/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287340
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293333
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293335
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293337
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647358
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647370
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647378
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647380
Principal investigator 1 Ipsen Innovation $10,000.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293233
Principal investigator 1 Ipsen Innovation $2,000.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293235
Principal investigator 1 Ipsen Innovation $1,800.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293237
Principal investigator 1 Ipsen Innovation $150.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287334
Principal investigator 1 Ipsen Innovation $90.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287336
Principal investigator 1 Ipsen Innovation $150.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287338
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307119
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307125
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307127
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307129
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307131
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307133
Principal investigator 1 Ipsen Innovation $2,000.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293217
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293219
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293221
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293223
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293225
Principal investigator 1 Ipsen Innovation $10,000.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293227
Principal investigator 1 Ipsen Innovation $1,800.00 08/20/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293215
Principal investigator 1 Ipsen Innovation $90.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287322
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287324
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287326
Principal investigator 1 Ipsen Innovation $180.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287328
Principal investigator 1 Ipsen Innovation $300.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287330
Principal investigator 1 Ipsen Innovation $300.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287332
Principal investigator 1 Ipsen Pharma SAS $4,676.00 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307121
Principal investigator 1 Ipsen Pharma SAS $4,676.00 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307123
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287316
Principal investigator 1 Ipsen Innovation $180.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287318
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287320
Principal investigator 1 Ipsen Innovation $175.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293101
Principal investigator 1 Ipsen Innovation $482.00 05/15/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287314
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,468.03 01/27/2025 Non-covered Recipient Entity
Hasbani Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997021
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $372,466.00 01/16/2025 Non-covered Recipient Entity
Hasbani Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997019